FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 12, 2024

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Takyiah Stevenson, PharmD
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Ranjana H. Advani, MD
Saul Rosenberg Professor of Lymphoma Division of Oncology
Stanford University School of Medicine
Stanford, California

Mark R. Conaway, PhD
Professor
Division of Translational Research and Applied Statistics
Department of Public Health Sciences
The University of Virginia School of Medicine
Charlottesville, Virginia

Christopher H. Lieu, MD
Associate Professor of Medicine
Associate Director for Clinical Research
Director, Gastrointestinal Medical Oncology
University of Colorado Cancer Center
Aurora, Colorado

Ravi A. Madan, MD
Senior Clinician
Head, Prostate Cancer Clinical Research Section
Genitourinary Malignancies Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

David E. Mitchell
(Consumer Representative)
President
Patients for Affordable Drugs
Bethesda, Maryland

Jorge J. Nieva, MD
Associate Professor of Clinical Medicine
Section Head, Solid Tumors
University of Southern California (USC)
Norris Comprehensive Cancer Center
Keck School of Medicine of USC
Los Angeles, California

Neil Vasan, MD, PhD
Assistant Professor
Division of Hematology & Oncology
Department of Medicine
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, New York
ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Tara Frenkl, MD, MPH
(Industry Representative)
Senior Vice President, Head of Oncology Development
Bayer Pharmaceuticals
Whippany, New Jersey

TEMPORARY MEMBERS (Voting)

Christopher Hourigan, DM, DPhil, FRCP
Director, Virginia Tech Fralin Biomedical Research Institute (FBRI) Cancer Research Center
Professor, FBRI
Professor, Virginia Tech Carillon School of Medicine
Washington, District of Columbia

Matthew J. Maurer, DMSc
Associate Professor of Biostatistics and Medicine
Division of Clinical Trials and Biostatistics
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Grzegorz (Greg) S. Nowakowski, MD, FASCO
(Acting Chairperson)
Professor of Medicine and Oncology
Deputy Director, Clinical Research
Mayo Clinic Comprehensive Cancer Center
Chair, Lymphoid Malignancy Group
Rochester, Minnesota

Michael A. Riotto
(Patient Representative)
Jamison, Pennsylvania

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD
Director, Oncology Center of Excellence (OCE)
Office of the Commissioner (OC)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Marc Theoret, MD
Deputy Center Director
OCE, OC
Supervisory Associate Director (Acting)
OOD, OND, CDER, FDA

Nicole Gormley, MD
Associate Director of Oncology Endpoint Development, OCE
Director, Division of Hematologic Malignancies II (DHM II)
OOD, OND, CDER, FDA

Bindu Kanapuru, MD
Associate Director of Therapeutic Review
DHM II, OOD, OND, CDER, FDA
<table>
<thead>
<tr>
<th>FDA PARTICIPANTS (Non-Voting) (cont.)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rachel Ershler, MD, MHS</strong></td>
<td><strong>Jonathan Vallejo, PhD</strong></td>
</tr>
<tr>
<td>Clinical reviewer</td>
<td>Biometrics Team Leader</td>
</tr>
<tr>
<td>DHM II, OOD, OND, CDER, FDA</td>
<td>Division of Biometrics IX (DBIX)</td>
</tr>
<tr>
<td></td>
<td>Office of Biostatistics (OB)</td>
</tr>
<tr>
<td></td>
<td>Office of Translational Sciences (OTS), CDER, FDA</td>
</tr>
<tr>
<td><strong>Jing Zhang, PhD</strong></td>
<td></td>
</tr>
<tr>
<td>Statistical Reviewer</td>
<td></td>
</tr>
<tr>
<td>DBIX, OB, OTS, CDER, FDA</td>
<td></td>
</tr>
</tbody>
</table>